Table 1. Results according to the outcomes of interest.
| Number of included studies | Number of patients evaluated | Estimated Effect (95% CI) | GRADE | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| Mirabegron | Antimuscarinics | I 2 | P | |||||
| Efficacy | Number of urinations/24h | 9 | 4232 | 3960 | MD: -0.00 (-0.16 to 0.16) | Low | 47% | 0.04 |
| Urge incontinence episodes/24h | 7 | 2281 | 1906 | MD: 0.08 (-0.02 to 0.17) | Low | 0% | 0.95 | |
| Emergency episodes/24h | 8 | 3926 | 3656 | MD: 0.04 (-0.10 to 0.19) | Low | 0% | 0.55 | |
| Episodes of urine leakage/24h | 9 | 2808 | 2477 | MD: 0.06 (-0.09 to 0.20) | Low | 34% | 0.13 | |
| Safety | Total Side Effects | 11 | 1879/4979 (37.7%) | 1898/4476 (42.4%) | RR: 0.93 (0.89 to 0.98) | Low | 7% | 0.38 |
| Gastrointestinal tract disorders (general) | 10 | 340/4939 (6.9%) | 556/4436 (12.5%) | RR: 0.58 (0.48 to 0.68) | Low | 31% | 0.14 | |
| Dry mouth | 10 | 180/4939 (3.6%) | 400/4436 (9.0%) | RR: 0.44 (0.35 to 0.56) | Low | 34% | 0.11 | |
| Constipation | 10 | 120/4939 (2.4%) | 119/4436 (2.7%) | RR: 0.95 (0.73 to 1.22) | Low | 0% | 0.97 | |
| Diarrhea | 2 | 18/1117 (1.6%) | 20/1115 (1.8%) | RR: 0.90 (0.48 to 1.69) | Low | 0% | 0.78 | |
| Dyspepsia | 4 | 10/2265 (0.4%) | 14/1755 (0.8%) | RR: 0.74 (0.32 to 1.72) | Very Low | 0% | 0.97 | |
| Nausea | 2 | 10/648 (1.5%) | 9/410 (2.2%) | RR: 0.76 (0.30 to 1.89) | Low | 0% | 0.91 | |
| CNS disorders (general) | 9 | 217/4560 (4.8%) | 172/4061 (4.2%) | RR: 1,14 (0.93 to 1.39) | Low | 0% | 0.81 | |
| Headache | 7 | 117/3349 (3.5%) | 93/3267 (2.8%) | RR: 1.22 (0.93 to 1.61) | Low | 0% | 0.91 | |
| Dizziness | 5 | 38/1967 (1.9%) | 34/1884 (1.8%) | RR: 1.00 (0.61 to 1.62) | Low | 0% | 0.55 | |
| Somnolence | 3 | 44/1469 (3.0%) | 30/1051 (2.9%) | RR: 1.03 (0.58 to 1.82) | Low | 28% | 0.25 | |
| Visual blur | 4 | 20/2255 (0.9%) | 18/1995 (0.9%) | RR: 1.12 (0.60 to 2.08) | Low | 0% | 0.69 | |
| Nasopharyngitis | 5 | 81/2131 (3.8%) | 76/2292 (3.3%) | RR: 1.18 (0.87 to 1.61) | Low | 0% | 0.96 | |
| Urinary retention | 5 | 4/3217 (0.1%) | 10/2797 (0.4%) | RR: 0.41 (0.14 to 1.26) | Low | 0% | 0.77 | |
| Urinary tract infection | 7 | 165/3795 (4.3%) | 183/3605 (5.1%) | RR: 0.87 (0.70 to 1.07) | Low | 0% | 0.97 | |
| Cardiac disorders | 10 | 147/4939 (3.0%) | 142/4436 (3.2%) | RR: 1.00 (0.74 to 1.35) | Low | 18% | 0.26 | |
| Hypertension | 9 | 175/4610 (3.8%) | 202/4351 (4.6%) | RR: 0.93 (0.76 to 1.13) | Low | 0% | 0.50 | |
| Adherence | 11 | 4175/4762 (87.7%) | 3549/4046 (87.7%) | RR: 0.99 (0.98 to 1.00) | Low | 2% | 0.43 | |
Abbreviations: CI, Confidence interval; CNS, Central nervous system; MD, Mean difference; RR, Risk ratio.